MedTrace Logo

Efficacy and Safety of Human Urinary Kallidinogenase for Acute Ischemic Stroke Patients Receiving Reperfusion Treatment

NCT06848894 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1204

Last updated 2025-03-28

No results posted yet for this study

Summary

This study aims to explore the efficacy and safety of Human Urinary Kallidinogenase for acute ischemic stroke patients receiving intravenous thrombolysis and/or endovascular treatment.

Conditions

  • Acute Ischemic Stroke

Interventions

DRUG

Human urinary kallidinogenase (HUK)

HUK (0.15 PNA) and sodium chloride injection (100ml), once per day

DRUG

Placebo

placebo (0 PNA) and sodium chloride injection (100ml), once per day

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    lead OTHER

Principal Investigators

  • Wang Yilong, MD, PhD · Beijing Tiantan Hospital

  • Wang Tingting, MD · Beijing Tiantan Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-31
Primary Completion
2026-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06848894 on ClinicalTrials.gov